The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as should have been, said Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
For those who missed it, what were some of the highlights from the House Energy and Commerce Committee hearing regarding the HHS budget for fiscal year 2023?
I think the highlights of that hearing mostly were, from a Biosimilars Forum perspective, it's what we didn't hear. We didn't hear enough about how HHS is going to do more to gain cost savings using biosimilars. How they're going to do more policies that we've been advocating for for years, [addressing] market barriers and improving access to biosimilars.
So, I think that was the most surprising thing for the Biosimilar Forum and our members. We heard a little bit about biosimilars. We've been saying, "Look, there's a solution right here to reduce prescription drug cost overall." It's such a critical, critical year for biosimilars, especially with the 7 biosimilars for Humira [adalimumab] launching next year.
So, we're going to go back and ask HHS to continue to support biosimilars and continue to work with them, especially on those upcoming launches. So, that was our takeaway, and it's now a greater priority for the Forum to get back to HHS.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.